Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 229 to 234 of 234 entries
Sorted by: Best Match Show Resources per page
Successful perioperative management of a pediatric patient with medium-chain acyl-CoA dehydrogenase deficiency using a continuous tissue glucose monitoring device: A case report.

Saudi journal of anaesthesia

Hidekazu I, Shoji M.
PMID: 34188645
Saudi J Anaesth. 2021 Apr-Jun;15(2):213-215. doi: 10.4103/sja.sja_1041_20. Epub 2021 Apr 01.

Medium-chain acyl-CoA dehydrogenase deficiency can cause symptoms resulting from β-oxidation disorder during preoperative fasting. Tight perioperative glucose monitoring is needed to avoid these symptoms. We report the first pediatric case using continuous tissue glucose monitoring devices. The patient was...

Cite
Hidekazu I, Shoji M. Successful perioperative management of a pediatric patient with medium-chain acyl-CoA dehydrogenase deficiency using a continuous tissue glucose monitoring device: A case report. Saudi J Anaesth. 2021;15(2):213-215doi: 10.4103/sja.sja_1041_20.
Hidekazu, I., & Shoji, M. (2021). Successful perioperative management of a pediatric patient with medium-chain acyl-CoA dehydrogenase deficiency using a continuous tissue glucose monitoring device: A case report. Saudi journal of anaesthesia, 15(2), 213-215. https://doi.org/10.4103/sja.sja_1041_20
Hidekazu, Ito, and Shoji, Mizuno. "Successful perioperative management of a pediatric patient with medium-chain acyl-CoA dehydrogenase deficiency using a continuous tissue glucose monitoring device: A case report." Saudi journal of anaesthesia vol. 15,2 (2021): 213-215. doi: https://doi.org/10.4103/sja.sja_1041_20
Hidekazu I, Shoji M. Successful perioperative management of a pediatric patient with medium-chain acyl-CoA dehydrogenase deficiency using a continuous tissue glucose monitoring device: A case report. Saudi J Anaesth. 2021 Apr-Jun;15(2):213-215. doi: 10.4103/sja.sja_1041_20. Epub 2021 Apr 01. PMID: 34188645; PMCID: PMC8191264.
Copy Download .nbib Format: NLM
Endurance exercise training-attenuated diabetic kidney disease with muscle weakness in spontaneously diabetic Torii fatty rats.

Kidney & blood pressure research

Kotake H, Yamada S, Ogura Y, Watanabe S, Inoue K, Ichikawa D, Sugaya T, Ohata K, Natsuki Y, Hoshino S, Watanabe M, Kimura K, Shibagaki Y, Kamijo-Ikemori A.
PMID: 34923497
Kidney Blood Press Res. 2021 Dec 17; doi: 10.1159/000521464. Epub 2021 Dec 17.

Background The aim of this study was to evaluate protective effects of endurance exercise training against diabetic kidney disease (DKD) with muscle weakness by using male spontaneously diabetic Torii (SDT) fatty rats as type 2 diabetic animal models with...

Cite
Kotake H, Yamada S, Ogura Y, et al. Endurance exercise training-attenuated diabetic kidney disease with muscle weakness in spontaneously diabetic Torii fatty rats. Kidney Blood Press Res. 2021;doi: 10.1159/000521464.
Kotake, H., Yamada, S., Ogura, Y., Watanabe, S., Inoue, K., Ichikawa, D., Sugaya, T., Ohata, K., Natsuki, Y., Hoshino, S., Watanabe, M., Kimura, K., Shibagaki, Y., & Kamijo-Ikemori, A. (2021). Endurance exercise training-attenuated diabetic kidney disease with muscle weakness in spontaneously diabetic Torii fatty rats. Kidney & blood pressure research, . https://doi.org/10.1159/000521464
Kotake, Hitoshi, et al. "Endurance exercise training-attenuated diabetic kidney disease with muscle weakness in spontaneously diabetic Torii fatty rats." Kidney & blood pressure research vol. (2021). doi: https://doi.org/10.1159/000521464
Kotake H, Yamada S, Ogura Y, Watanabe S, Inoue K, Ichikawa D, Sugaya T, Ohata K, Natsuki Y, Hoshino S, Watanabe M, Kimura K, Shibagaki Y, Kamijo-Ikemori A. Endurance exercise training-attenuated diabetic kidney disease with muscle weakness in spontaneously diabetic Torii fatty rats. Kidney Blood Press Res. 2021 Dec 17; doi: 10.1159/000521464. Epub 2021 Dec 17. PMID: 34923497.
Copy Download .nbib Format: NLM
Jiuzhuan Huangjing Pills relieve mitochondrial dysfunction and attenuate high-fat diet-induced metabolic dysfunction-associated fatty liver disease.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Mu JK, Zi L, Li YQ, Yu LP, Cui ZG, Shi TT, Zhang F, Gu W, Hao JJ, Yu J, Yang XX.
PMID: 34449316
Biomed Pharmacother. 2021 Oct;142:112092. doi: 10.1016/j.biopha.2021.112092. Epub 2021 Aug 27.

BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a common global chronic liver disease. Jiuzhuan Huangjing Pills (JHP) have been used for the treatment of human disease for over a thousand years, but their efficacy and underlying mechanism(s) of...

Cite
Mu JK, Zi L, Li YQ, et al. Jiuzhuan Huangjing Pills relieve mitochondrial dysfunction and attenuate high-fat diet-induced metabolic dysfunction-associated fatty liver disease. Biomed Pharmacother. 2021;142:112092doi: 10.1016/j.biopha.2021.112092.
Mu, J. K., Zi, L., Li, Y. Q., Yu, L. P., Cui, Z. G., Shi, T. T., Zhang, F., Gu, W., Hao, J. J., Yu, J., & Yang, X. X. (2021). Jiuzhuan Huangjing Pills relieve mitochondrial dysfunction and attenuate high-fat diet-induced metabolic dysfunction-associated fatty liver disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 142112092. https://doi.org/10.1016/j.biopha.2021.112092
Mu, Jian-Kang, et al. "Jiuzhuan Huangjing Pills relieve mitochondrial dysfunction and attenuate high-fat diet-induced metabolic dysfunction-associated fatty liver disease." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 142 (2021): 112092. doi: https://doi.org/10.1016/j.biopha.2021.112092
Mu JK, Zi L, Li YQ, Yu LP, Cui ZG, Shi TT, Zhang F, Gu W, Hao JJ, Yu J, Yang XX. Jiuzhuan Huangjing Pills relieve mitochondrial dysfunction and attenuate high-fat diet-induced metabolic dysfunction-associated fatty liver disease. Biomed Pharmacother. 2021 Oct;142:112092. doi: 10.1016/j.biopha.2021.112092. Epub 2021 Aug 27. PMID: 34449316.
Copy Download .nbib Format: NLM
Enzyme analyses demonstrate that beta-methylbutyric acid is converted to beta-hydroxy-beta-methylbutyric acid via the leucine catabolic pathway by galactomyces reessii .

Archives of microbiology

Lee IY, Rosazza JPN.
PMID: 9477261
Arch Microbiol. 1998 Mar;169(3):257-62. doi: 10.1007/s002030050569.

Galactomyces reessii accomplishes the enzymatic transformation of beta-methylbutyric acid (isovaleric acid) to beta-hydroxy-beta-methylbutyric acid. The enzymatic basis for this bioconversion was evaluated by analyzing cell-free extracts of G. reessii for enzyme activities commonly associated with leucine catabolism. G. reessii...

Cite
Lee IY, Rosazza JPN. Enzyme analyses demonstrate that beta-methylbutyric acid is converted to beta-hydroxy-beta-methylbutyric acid via the leucine catabolic pathway by galactomyces reessii . Arch Microbiol. 1998;169(3):257-62doi: 10.1007/s002030050569.
Lee, I. Y., & Rosazza, J. P. N. (1998). Enzyme analyses demonstrate that beta-methylbutyric acid is converted to beta-hydroxy-beta-methylbutyric acid via the leucine catabolic pathway by galactomyces reessii . Archives of microbiology, 169(3), 257-62. https://doi.org/10.1007/s002030050569
Lee, and Rosazza. "Enzyme analyses demonstrate that beta-methylbutyric acid is converted to beta-hydroxy-beta-methylbutyric acid via the leucine catabolic pathway by galactomyces reessii ." Archives of microbiology vol. 169,3 (1998): 257-62. doi: https://doi.org/10.1007/s002030050569
Lee IY, Rosazza JPN. Enzyme analyses demonstrate that beta-methylbutyric acid is converted to beta-hydroxy-beta-methylbutyric acid via the leucine catabolic pathway by galactomyces reessii . Arch Microbiol. 1998 Mar;169(3):257-62. doi: 10.1007/s002030050569. PMID: 9477261.
Copy Download .nbib Format: NLM
Patient and family engagement in the development of core outcome sets for two rare chronic diseases in children.

Research involvement and engagement

Vanderhout SM, Smith M, Pallone N, Tingley K, Pugliese M, Chakraborty P, Stockler S, Offringa M, Butcher N, Nicholls SG, Potter BK.
PMID: 34521478
Res Involv Engagem. 2021 Sep 14;7(1):66. doi: 10.1186/s40900-021-00304-y.

BACKGROUND: Core outcome sets (COS) are lists of consensus-determined outcomes to be measured and reported in all clinical research studies within a disease area. While including patients and families in COS development to improve their relevance and applicability to...

Cite
Vanderhout SM, Smith M, Pallone N, et al. Patient and family engagement in the development of core outcome sets for two rare chronic diseases in children. Res Involv Engagem. 2021;7(1):66doi: 10.1186/s40900-021-00304-y.
Vanderhout, S. M., Smith, M., Pallone, N., Tingley, K., Pugliese, M., Chakraborty, P., Stockler, S., Offringa, M., Butcher, N., Nicholls, S. G., & Potter, B. K. (2021). Patient and family engagement in the development of core outcome sets for two rare chronic diseases in children. Research involvement and engagement, 7(1), 66. https://doi.org/10.1186/s40900-021-00304-y
Vanderhout, Shelley M, et al. "Patient and family engagement in the development of core outcome sets for two rare chronic diseases in children." Research involvement and engagement vol. 7,1 (2021): 66. doi: https://doi.org/10.1186/s40900-021-00304-y
Vanderhout SM, Smith M, Pallone N, Tingley K, Pugliese M, Chakraborty P, Stockler S, Offringa M, Butcher N, Nicholls SG, Potter BK. Patient and family engagement in the development of core outcome sets for two rare chronic diseases in children. Res Involv Engagem. 2021 Sep 14;7(1):66. doi: 10.1186/s40900-021-00304-y. PMID: 34521478; PMCID: PMC8439069.
Copy Download .nbib Format: NLM
The Mitochondrial Antioxidant Sirtuin3 Cooperates with Lipid Metabolism to Safeguard Neurogenesis in Aging and Depression.

Cells

Santos SS, Moreira JB, Costa M, Rodrigues RS, Sebastião AM, Xapelli S, Solá S.
PMID: 35011652
Cells. 2021 Dec 29;11(1). doi: 10.3390/cells11010090.

Neural stem cells (NSCs), crucial for memory in the adult brain, are also pivotal to buffer depressive behavior. However, the mechanisms underlying the boost in NSC activity throughout life are still largely undiscovered. Here, we aimed to explore the...

Cite
Santos SS, Moreira JB, Costa M, et al. The Mitochondrial Antioxidant Sirtuin3 Cooperates with Lipid Metabolism to Safeguard Neurogenesis in Aging and Depression. Cells. 2021;11(1)doi: 10.3390/cells11010090.
Santos, S. S., Moreira, J. B., Costa, M., Rodrigues, R. S., Sebastião, A. M., Xapelli, S., & Solá, S. (2021). The Mitochondrial Antioxidant Sirtuin3 Cooperates with Lipid Metabolism to Safeguard Neurogenesis in Aging and Depression. Cells, 11(1), . https://doi.org/10.3390/cells11010090
Santos, Sónia Sá, et al. "The Mitochondrial Antioxidant Sirtuin3 Cooperates with Lipid Metabolism to Safeguard Neurogenesis in Aging and Depression." Cells vol. 11,1 (2021). doi: https://doi.org/10.3390/cells11010090
Santos SS, Moreira JB, Costa M, Rodrigues RS, Sebastião AM, Xapelli S, Solá S. The Mitochondrial Antioxidant Sirtuin3 Cooperates with Lipid Metabolism to Safeguard Neurogenesis in Aging and Depression. Cells. 2021 Dec 29;11(1). doi: 10.3390/cells11010090. PMID: 35011652; PMCID: PMC8750385.
Copy Download .nbib Format: NLM
Showing 229 to 234 of 234 entries